Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand

被引:83
作者
Gomez, Y [1 ]
Adams, E [1 ]
Hoogmartens, J [1 ]
机构
[1] Katholieke Univ Leuven, Fac Farmaceut Wetenschappen, Lab Farmaceut Chem & Anal Geneesmiddelen, B-3000 Louvain, Belgium
关键词
clopidogrel; copies; liquid chromatography; dissolution;
D O I
10.1016/S0731-7085(03)00533-8
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, 18 copies of PLAVIX((R)) tablets containing clopidogrel hydrogensulfate were compared to the innovator drug product for uniformity of mass, impurity profile, content, dissolution properties and stability. In order to be able to separate the R-enantiomer of clopidogrel, an enantiospecific liquid chromatographic method was used to determine the impurities and to perform the assay. The paddle method was used for dissolution testing. Most of the copies were not similar compared to the original drug product: their amount of impurities was higher, the content of clopidogrel lower, the dissolution profiles different and after 3 months under stress conditions in the original packaging, the results for the samples and the reference were significantly different in most of the cases. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:341 / 348
页数:8
相关论文
共 11 条
  • [1] Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
    Bertrand, ME
    Rupprecht, HJ
    Urban, P
    Gershlick, AH
    [J]. CIRCULATION, 2000, 102 (06) : 624 - 629
  • [2] *EUR DEP QUAL MED, 2002, EUR PHARM
  • [3] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    Gent, M
    Beaumont, D
    Blanchard, J
    Bousser, MG
    Coffman, J
    Easton, JD
    Hampton, JR
    Harker, LA
    Janzon, L
    Kusmierek, JJE
    Panak, E
    Roberts, RS
    Shannon, JS
    Sicurella, J
    Tognoni, G
    Topol, EJ
    Verstraete, M
    Warlow, C
    [J]. LANCET, 1996, 348 (9038) : 1329 - 1339
  • [4] *ICH, 1996, ICH TRIP GUID Q3B IM
  • [5] Clopidogrel - A review of its use in the prevention of atherothrombosis
    Jarvis, B
    Simpson, K
    [J]. DRUGS, 2000, 60 (02) : 347 - 377
  • [6] A validated LC method for the determination of clopidogrel in pharmaceutical preparations
    Mitakos, A
    Panderi, I
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (3-4) : 431 - 438
  • [7] Reist M, 2000, DRUG METAB DISPOS, V28, P1405
  • [8] SAVI P, 1994, THROMB HAEMOSTASIS, V72, P313
  • [9] United States Pharmacopeial Convention, 2000, US PHARM, V23rd
  • [10] Yusuf S, 2001, NEW ENGL J MED, V345, P494